Top Markets
Coin of the day
Crescita Therapeutics Inc. Crescita Therapeutics Inc.

Crescita Therapeutics Inc.

CTX
Rang în acțiuni #32190
Crescita Therapeutics Inc. is a dermatology-focused enterprise that offers a... Crescita Therapeutics Inc. is a dermatology-focused enterprise that offers a comprehensive portfolio of both over-the-counter skincare products and prescription medications, distributed across Canada, the United States, and other international markets. The company operates through three principal divisions: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. Central to its innovation are proprietary platform technologies, MMPE and DuraPeel, which are specifically employed in the formulation of topical treatments containing cannabis and hemp compounds. Crescita's prescription drug lineup includes Pliaglis, a topical local anesthetic cream designed to provide dermal analgesia on intact skin prior to superficial dermatological procedures. Its development pipeline features CTX-101, a Phase III topical corticosteroid formulation utilizing MMPE technology for treating plaque psoriasis, and CTX-102, a Phase I topical therapy leveraging MMPE for an unspecified skin condition. Furthermore, several pre-clinical dermatology products are in development, also based on MMPE technology, for various prescription skin disease treatments. In the non-prescription sector, Crescita offers a broad selection of skincare items. Under the Laboratoire Dr Renaud brand, it provides facial creams, cleansers, exfoliants, masks, serums, and suncare products aimed at addressing concerns such as aging, acne, rosacea, pigmentation, dehydration, and sensitivity. The Pro-Derm line consists of dermocosmetic solutions specifically formulated for anti-aging medical procedures, while the Alyria brand targets a diverse range of skincare issues. Products under the Dermazulene brand are primarily intended for Asian consumers. The company also markets NCTF 135 HA, a skin revitalization solution focused on improving skin quality and reducing fine lines. Crescita has established key collaborations, including a development and licensing agreement with Sundial Growers Inc. for cannabis product development, a commercialization license agreement with Cantabria Labs Inc., and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was founded in 2016 and maintains its corporate headquarters in Laval, Canada.
Preț acțiune
$0.57981014
Ultima sincronizare: 2026-06-04
Capitalizare de piață
$10.79M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
61.64%
Țară
CA
Tranzacționează Crescita Therapeutics Inc. (CTX)

Categorie

Raport P/E pentru Crescita Therapeutics Inc. (CTX)
Raport P/E la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Crescita Therapeutics Inc., raportul P/E actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/E de 0.
Istoricul raportului P/E pentru Crescita Therapeutics Inc. din 2026 până în 2026
Raportul P/E la sfârșitul fiecărui an
An Raport P/E Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raportul P/E pentru companii similare sau concurenți
Cum interpretezi un P/E ratio?

Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.

Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.

Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.